Nasopharyngeal Carcinoma

P3, N=700, Recruiting, Sun Yat-sen University | Trial completion date: Nov 2032 --> Nov 2031 | Trial primary completion date: Nov 2030 --> Nov 2029

The patient was treated with six cycles of rituximab-bendamustine, resulting in complete regression of the nasopharyngeal mass and reduction in splenomegaly, with minimal residual lymphadenopathy and good clinical and biological tolerance. This case highlights the importance of considering CLL in the differential diagnosis of nasopharyngeal masses and emphasizes the role of combined imaging, histology, and immunophenotyping in establishing an accurate diagnosis and guiding appropriate management.

Complete surgical excision with negative margins is the treatment of choice, and follow-up is crucial to detect recurrence. This case highlights the importance of early recognition and accurate diagnosis of HCCC to ensure curative surgical outcomes and prevent metastasis.

Moreover, the expression levels of PRMT5 and EphA2 in the NPC tissues were significantly higher than those in the normal nasopharyngeal mucosal tissues, and both proteins for predicting the patient's prognosis are superior to individual proteins. Our findings suggest that PRMT5 methylates and stabilizes EphA2 to promote NPC stem cell properties, and the PRMT5-derived peptide P20 can serve as a novel strategy for targeting EphA2 degradation and inhibiting NPC stem cell properties.

After discontinuing the drug and giving continuous norepinephrine to increase BP, the patient's BP returned to stable. This case suggests that although nimotuzumab-related hypotension is mostly mild and reversible, BP monitoring should still be strengthened to maintain vigilance against severe hypotension and intervene promptly in clinical practice.

P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

P2, N=59, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting

These findings indicate that adding nimotuzumab to CCRT does not improve survival in patients with LA-NPC with a suboptimal response to IC, underscoring the need for predictive biomarkers and alternative therapeutic strategies. Trial registration: NCT04223024.

This dynamic model identified primary refractory disease more accurately than single-marker kinetics. The CRP-LDH-based IRI, both at baseline and during early treatment, is a practical tool for stratifying prognosis and dynamically monitoring response to PD-1 inhibitors in RM-NPC, which supports ongoing clinical evaluation.

Moreover, the small molecule inhibitor FL118 was able to disrupt this process by promoting DDX5 degradation, unveiling FL118 as a new potential antiviral drug. Our findings established a new functional axis of EBNA1/DDX5/BZLF1, adding to the knowledge about the role of EBNA1 in the regulation of EBV life cycle, particularly for lytic replication. The study also provided potential therapeutic strategy for EBV-associated epithelial tumors.

P1/2, N=31, Not yet recruiting, Singapore General Hospital | Initiation date: Jan 2026 --> Apr 2026

We therefore characterized the impact of pan-HDAC inhibitor, panobinostat, and class I HDAC inhibitor, nanatinostat, on the growth, survival, and lytic reactivation of four EBV-positive cell lines: P3HR1-ZHT BL, Jijoye BL, IBL-1 immunoblastic lymphoma, and de novo infection derived lymphoblastoid cell lines (LCL). Functional validation through a Cas9-RNP approach revealed that the CD137 receptor is indeed involved in preventing successful lytic reactivation. These data have important implications for how we approach oncolytic therapies for EBV-associated malignancies.